DNA Methylation Market Top Leaders and Growth
- Illumina, Inc.
- Thermo Fisher Scientific
- QIAGEN N.V.
- New England Biolabs
- Zymo Research Corporation
- Active Motif, Inc.
- Diagenode S.A.
- Merck KGaA
- Agilent Technologies
- Roche Diagnostics
- Pacific Biosciences
- Oxford Nanopore Technologies
- Bio-Rad Laboratories
- Abcam plc
- EpiGentek Group, Inc.
- PerkinElmer, Inc.
- BGI / MGI
- Exact Sciences
- Epigenomics AG
- EpigenDx
Market Trends
The global DNA methylation market size reached USD 1.8 billion in 2024, grew to USD 2.05 billion in 2025, and is projected to hit around USD 6.45 billion by 2034, expanding at a CAGR of 13.64% during the forecast period from 2025 to 2034.
What are the Major Drifts in the DNA Methylation Market?
- The venture capital funds focus on collaborative work with global entrepreneurs to improve therapeutic programs with the aim of addressing potential medical needs. For instance, in July 2025, Venture Firm Frazier reported the closing of a $1.3 billion fund for an early-stage biotechnology investment.
- The startup is using CRISPR tools to stop the expression of a gene that is associated with facioscapulohumeral muscular dystrophy. For instance, in March 2025, Epicrispr declared an investment of $68 million to test epigenetic editing on a rare muscle disease or a rare neuromuscular disorder known as facioscapulohumeral muscular dystrophy.
DNA Methylation Market Value Chain Analysis
R&D
The R&D process for DNA methylation includes key aspects such as defining a research hypothesis, selection of a methylation detection method, sample collection, sample preparation, execution of the methylation detection method, and several other key considerations.
Key Players: Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., New England Biolabs, Agilent Technologies Inc.
Distribution to Hospitals, Pharmacies
Hospitals and pharmacies contribute to the acceptance of specialized kits, reagents, instruments, software, etc., from the distribution channels and the leading companies like Zymo Research, Thermo Fisher Scientific Inc., Illumina Inc., and QIAGEN.
Key Players: Exact Sciences, Agilent Technologies, Bio-Rad Laboratories, New England Biolabs.
Patient Support and Services
DNA methylation plays a key role in early diagnosis of health conditions, risk assessment, guiding personalized treatments, disease monitoring, patient education, and counseling.
Key Players: Freenome, Inherent Biosciences, Inc., Nucleix Ltd., GRAIL, DNA Labs India.
Latest Announcement by Industry Leaders
In January 2024, Dominic John, Vice President, QIAGEN Digital Insights, proclaimed that the launch of Ingenuity Pathway Analysis (IPA) stands as a breakthrough in molecular data analysis, which combines human expertise and AI technology.
Recent Developments in the DNA Methylation Market
- In May 2025, Ellis Bio announced the launch of the SuperMethyl™ - Fast Bisulfite Conversion Kit at the Chicago Biomedical Consortium, which will revolutionize epigenomics research.
- In November 2024, Self-Screen announced the launch of an essential tool named ‘Methylated DNA Control Sample’ that will assist researchers in conducting methylation-specific PCR |(qMSP) testing and bisulfite conversion.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
